XML 44 R33.htm IDEA: XBRL DOCUMENT
v3.26.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Schedule of estimated useful lives of property, plant and equipment | The Company's property, plant, and equipment primarily consists of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives: ​
​ | ​ | ​
Production equipment | ​ ​ ​ | 3 to 13 years
Office furniture and equipment |  | 3 to 10 years
Buildings |  | 39 years
Building improvements |  | 5 to 15 years
​
Schedule of significant customers | The following table reflects the Company’s significant customers in 2025, 2024, and 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Years Ended December 31, |
​ | ​ ​ ​ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023 |
Number of significant customers |  |  | ​ | 3 | ​ | ​ | 3 |  | ​ | 4 | ​
Aggregate dollar amount of net sales to significant customers | ​ | ​ | $ | 20.6 million | ​ | $ | 17.8 million | ​ | $ | 25.9 million | ​
Percentage of net sales to significant customers | ​ | ​ | ​ | 53.9 | % | ​ | 53.8 | % | ​ | 61.3 | %
​
Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized | Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2025:
​ | ​ ​ ​ | ​ | ​ | ​ ​ ​ | Blood | ​ ​ ​ | ​ | ​ | ​ ​ ​ | ​ | ​ | ​ ​ ​ | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 21,082,703 | ​ | ​ | 1,344,293 | ​ | ​ | 9,779,025 | ​ | ​ | 30,878 | ​ | $ | 32,236,899
North and South America sales (excluding U.S.) | ​ |  | 3,185,850 | ​ | ​ | — | ​ | ​ | 1,874,848 | ​ | ​ | — | ​ | ​ | 5,060,698
Other international sales | ​ |  | 641,403 | ​ | ​ | 25,698 | ​ | ​ | 288,764 | ​ | ​ | 12,749 | ​ | ​ | 968,614
Total | ​ | $ | 24,909,956 | ​ | $ | 1,369,991 | ​ | $ | 11,942,637 | ​ | $ | 43,627 | ​ | $ | 38,266,211
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2024:
​ | ​ ​ ​ | ​ | ​ | ​ ​ ​ | Blood | ​ ​ ​ | ​ | ​ | ​ ​ ​ | ​ | ​ | ​ ​ ​ | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 19,491,747 | ​ | ​ | 1,259,289 | ​ | ​ | 8,595,794 | ​ | ​ | 27,315 | ​ | $ | 29,374,145
North and South America sales (excluding U.S.) | ​ |  | 1,895,393 | ​ | ​ | 96 | ​ | ​ | 59,040 | ​ | ​ | 6,240 | ​ |  | 1,960,769
Other international sales | ​ |  | 1,242,748 | ​ | ​ | 166,222 | ​ | ​ | 293,352 | ​ | ​ | 12,297 | ​ |  | 1,714,619
Total | ​ | $ | 22,629,888 | ​ | $ | 1,425,607 | ​ | $ | 8,948,186 | ​ | $ | 45,852 | ​ | $ | 33,049,533
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2023:
​ | ​ ​ ​ | ​ | ​ | ​ ​ ​ | Blood | ​ ​ ​ | ​ | ​ | ​ ​ ​ | ​ | ​ | ​ ​ ​ | ​
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Total
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Revenue
U.S. sales (excluding U.S. government) | ​ | $ | 26,119,940 | ​ | ​ | 1,414,783 | ​ | ​ | 7,031,798 | ​ | ​ | 33,233 | ​ | $ | 34,599,754
North and South America sales (excluding U.S.) | ​ | ​ | 5,858,726 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 226,440 | ​ |  | 6,085,166
Other international sales | ​ | ​ | 2,176,674 | ​ | ​ | 511,788 | ​ | ​ | 216,944 | ​ | ​ | 6,600 | ​ |  | 2,912,006
Total | ​ | $ | 34,155,340 | ​ | $ | 1,926,571 | ​ | $ | 7,248,742 | ​ | $ | 266,273 | ​ | $ | 43,596,926
​
Schedule of potential dilution | The calculation of diluted EPS under the treasury stock method included the following shares in 2025, 2024, and 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Years Ended December 31,
​ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Common stock underlying issued and outstanding stock options | ​ | — | ​ | — | ​ | 15,040
​ | ​ | — | ​ | — | ​ | 15,040
​
Schedule of diluted EPS under the treasury stock method | The potential dilution, if any, is shown on the following schedule: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Years Ended December 31,
​ | ​ ​ ​ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Net loss | ​ | ​ | $ | (12,565,230) | ​ | $ | (11,886,524) | ​ | $ | (7,011,036)
Preferred stock dividend requirements | ​ | ​ |  | (230,444) | ​ |  | (230,444) | ​ |  | (231,946)
Loss applicable to common shareholders | ​ | ​ | $ | (12,795,674) | ​ | $ | (12,116,968) | ​ | $ | (7,242,982)
Average common shares outstanding | ​ | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159
Average common and common equivalent shares outstanding — diluted | ​ | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159
Basic loss per share | ​ | ​ | $ | (0.43) | ​ | $ | (0.40) | ​ | $ | (0.24)
Diluted loss per share | ​ | ​ | $ | (0.43) | ​ | $ | (0.40) | ​ | $ | (0.24)

X
- Definition Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + References No definition available. + Details
Name: | rvp_UsefulLifeOfPropertyPlantAndEquipmentTableTextBlock
Namespace Prefix: | rvp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration